RNF113B Activators can be understood as chemicals that indirectly influence the activity of RNF113B, a protein involved in the DNA damage response and the ubiquitin-proteasome system. These compounds generally function either by causing DNA damage, thereby inducing the DNA damage response involving RNF113B, or by inhibiting the proteasome, thereby potentially affecting the ubiquitin-proteasome system involving RNF113B. For instance, hydroxyurea, doxorubicin, cisplatin, etoposide, camptothecin, and bleomycin can induce DNA damage, thereby potentially inducing the DNA damage response involving RNF113B. Moreover, MG132, bortezomib, carfilzomib, MLN2238, epoxomicin, and marizomib function by inhibiting the proteasome, thereby potentially affecting the ubiquitin-proteasome system involving RNF113B.
SEE ALSO...
Items 11 to 11 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin inhibits the proteasome, potentially affecting the ubiquitin-proteasome system involving RNF113B. |